Ribupatide: Side Effects

Safety Overview#

Ribupatide (HRS9531) has demonstrated a favorable safety profile in Phase 2 trials for both injectable and oral formulations. The adverse event profile is consistent with the GLP-1/GIP receptor agonist class, with gastrointestinal events being the most common. Notably, no permanent discontinuations due to gastrointestinal events were reported in the injectable Phase 2 trial.

Gastrointestinal Adverse Events#

The most common adverse events are gastrointestinal, consistent with the dual incretin agonist mechanism:

Injectable Formulation#

• Nausea: 11.9-22.7% across dose groups
• Vomiting: 2.4-11.4% across dose groups
• Diarrhea: Commonly reported, mild to moderate

Most gastrointestinal adverse events were mild and occurred primarily during the dose titration phase. The safety profile was described as favorable and consistent with other GLP-1/GIP receptor agonist class drugs. No permanent discontinuations due to GI events were reported.

Oral Formulation#

Safety data from the oral Phase 2 trial have not been fully disclosed. The oral formulation demonstrated safety and tolerability consistent with the GLP-1/GIP receptor agonist class. Specific adverse event rates were not included in the press release.

GLP-1/GIP Agonist Class Warnings#

As a dual GLP-1/GIP receptor agonist, ribupatide is expected to carry the same class-wide safety considerations as tirzepatide:

• Thyroid C-cell tumors: Class-wide boxed warning based on rodent data
• Pancreatitis: Potential risk based on class effects
• Gallbladder events: Weight loss may increase cholelithiasis risk
• Injection site reactions: Possible with subcutaneous formulation

Safety Highlights#

The relatively low rates of gastrointestinal adverse events and the absence of discontinuations due to GI events are noteworthy, particularly given the magnitude of weight loss achieved. This may reflect effective dose titration protocols or favorable tolerability characteristics of the molecule.

Limitations of Safety Data#

• Safety data primarily from Phase 2 trials with limited participant numbers
• Primarily Chinese population data
• Maximum treatment duration of 36-52 weeks
• Full safety data from Phase 2 trials not yet peer-reviewed
• No post-marketing surveillance data

Safety Profile Context#

Ribupatide belongs to the Metabolic category of research peptides. Understanding the side effect profile of Ribupatide is essential for researchers designing clinical protocols and for healthcare providers advising patients. The side effects documented here are based on available clinical trial data and may not represent the complete safety profile.

Reported Side Effects#

The following side effects have been documented in clinical studies of Ribupatide. Side effect severity and frequency are based on available clinical data.

Nausea#

Severity: mild | Frequency: common

Reported in 11.9-22.7% of participants across clinical trials. Predominantly mild to moderate. Most common during dose titration and tends to diminish with continued treatment.

Vomiting#

Severity: mild | Frequency: common

Reported in 2.4-11.4% of participants. Mild to moderate severity. No permanent discontinuations due to GI events reported.

Diarrhea#

Severity: mild | Frequency: common

Reported as a common adverse event. Generally mild to moderate and self-limiting.

Decreased appetite#

Severity: mild | Frequency: common

Commonly reported, consistent with GLP-1/GIP dual agonist mechanism. Generally considered a therapeutic effect.

Contraindications#

The following contraindications have been identified for Ribupatide based on available research and pharmacological considerations:

• Investigational compound: not approved for clinical use; use only within clinical trial context
• Expected class contraindications: personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome
• Pregnancy and breastfeeding (expected contraindication based on class)

Individuals with any of these conditions should not use Ribupatide without consulting a qualified healthcare provider.

Drug Interactions#

The following potential drug interactions have been identified for Ribupatide:

• Insulin and sulfonylureas: increased hypoglycemia risk expected based on GLP-1/GIP agonist class effects
• Oral medications: delayed gastric emptying may affect absorption of co-administered oral drugs

Drug interaction studies for Ribupatide remain limited. Researchers should exercise caution when combining Ribupatide with other compounds and consult relevant pharmacological references.

Related Reading#

• Ribupatide overview and research guide
• Ribupatide dosing protocols
• Ribupatide risks and legal status